NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Ltd. Kck Sells 3,123 Shares

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 3,123 shares of the firm’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $6.10, for a total value of $19,050.30. Following the sale, the insider now directly owns 5,530,981 shares in the company, valued at approximately $33,738,984.10. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The shares were sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The shares were sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The stock was sold at an average price of $6.35, for a total value of $16,332.20.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total value of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The stock was sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Trading Down 1.1 %

NASDAQ:NPCE traded down $0.07 on Friday, reaching $6.32. The company’s stock had a trading volume of 5,487 shares, compared to its average volume of 96,048. NeuroPace, Inc. has a 12-month low of $5.73 and a 12-month high of $18.15. The company has a quick ratio of 5.47, a current ratio of 6.37 and a debt-to-equity ratio of 5.97. The firm has a market cap of $181.81 million, a price-to-earnings ratio of -5.31 and a beta of 1.78. The stock has a 50 day moving average price of $7.06 and a 200 day moving average price of $8.46.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. The company had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.30 million. During the same quarter in the previous year, the business earned ($0.36) earnings per share. The company’s revenue for the quarter was up 16.6% on a year-over-year basis. On average, equities analysts anticipate that NeuroPace, Inc. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wells Fargo & Company cut their price objective on NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research note on Wednesday, August 14th. Finally, Morgan Stanley lowered their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, NeuroPace presently has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Institutional Investors Weigh In On NeuroPace

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NPCE. Millennium Management LLC raised its holdings in shares of NeuroPace by 13.3% in the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after buying an additional 80,324 shares during the period. Vanguard Group Inc. raised its holdings in shares of NeuroPace by 18.3% in the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after buying an additional 75,512 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of NeuroPace in the 1st quarter valued at $621,000. Bank of New York Mellon Corp purchased a new stake in shares of NeuroPace in the 2nd quarter valued at $257,000. Finally, Rhumbline Advisers purchased a new stake in shares of NeuroPace in the 2nd quarter valued at $111,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.